Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons.
Recombinant tick anticoagulant peptide (r-TAP) is a potent and specific inhibitor of activated coagulation factor X which effectively interrupts in vivo arterial thrombosis during treatment. It is, however, uncertain if it also affects thrombosis after treatment is stopped. This was tested in a baboon model of arterial thrombosis where platelet deposition onto Dacron vascular graft segments, inserted as extensions into permanent femoral arteriovenous shunts, was measured. The baboons were intravenously treated with 10 micrograms/kg/min (low dose, aPTT = 39 +/- 1 s) and 25 micrograms/kg/min (high dose, aPTT = 58 +/- 2 s) r-TAP for two hours. During treatment the r-TAP inhibited thrombin formation and dose-dependently interrupted platelet deposition onto the graft segment. This effect lasted for up to two hours after treatment with the low dose. Following treatment with the high dose, the graft segments were kept in place for 53 h. After treatment was stopped, platelets again deposited, but at a much lower rate than in control studies. Maximum deposition was approximately 38% lower than in the control studies. Total platelet deposition over 55 h, calculated as the area under the deposition curve, was approximately 40% (p < 0.05) less than in the control studies. A significant shortening in the mean platelet life span and an approximately 15-fold increase in thrombin-antithrombin III complexes during the first 31 h indicated that the thrombus surface remained thrombogenic and that the effect of r-TAP was transient. We have shown that 2 h of treatment with a full antithrombotic dose of r-TAP markedly reduced both the rate of platelet deposition after treatment was stopped and the total number of platelets deposited over 55 h. This was in spite of the finding that the antithrombotic effect of r-TAP was transient.
Kotzé
H F
HF
Department of Haematology, University of The Free State, Bloemfontein, Republic of South Africa. GNHMHK@MED.UOVS.AC.ZA
Lamprecht
S
S
Badenhorst
P N
PN
Roodt
J P
JP
van Wyk
V
V
D000818:Animals; D001158:Arteries / Q000473:pathology*; D060829:Arthropod Proteins; D065427:Factor Xa Inhibitors; D007262:Infusions, Intravenous; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D010215:Papio; D010455:Peptides / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage*; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage*; D013927:Thrombosis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D060829:Arthropod Proteins; D065427:Factor Xa Inhibitors; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors; C063967:tick anticoagulant peptide